POS-143 BENRAZILUMAB SUBSTITUTION MONOTHERAPY IS EFFECTIVE IN SYMPTOMATIC ASTHMA EXACERBATIONS OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Recently, there has been increasing interest in the use of biologicals including anti-interleukin 5 antibodies and anti-interleukin 5 receptor antibodies in the management of steroid-resistant and/or steroid-dependent eosinophilic granulomatosis with polyangiitis (EGPA). Benralizumab, an anti-IL 5 receptor antibody is steroid sparing. We describe the successful substitution Benralizumab montherapy in a patient with asthma-dominant EGPA.